Immune Checkpoint Inhibitors and Pre-existing Autoimmune Diseases
The tolerance of immune checkpoint inhibitors is unknown in patients with pre-existing autoimmune conditions. This retrospective nation-wide study will assess their tolerance in patients with pre-existing autoimmune conditions who received immune checkpoint inhibitors for an advanced cancer in clinical practice.
Autoimmune Diseases|Advanced Cancer
DRUG: Checkpoint inhibitor therapy
Autoimmune disease flare, Increase in the activity of the pre-existing autoimmune disease as assessed by the treating physician, through study completion, an average of 1 year
Other immune/inflammatory complications, Development of a new immune/inflammatory condition after the start of the therapy, through study completion, an average of 1 year
The tolerance of immune checkpoint inhibitors is unknown in patients with pre-existing autoimmune conditions. This retrospective nation-wide study will assess their tolerance in patients with pre-existing autoimmune conditions who received immune checkpoint inhibitors for an advanced cancer in clinical practice.